Relationship between therapeutic efficacy of arterial infusion chemotheraphy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 12, Issue 6, 2006, Pages 868-873

  Akimoto, Masahide ^a   Yoshikawa, Masaharu ^a   Ebara, Masaaki ^a   Sato, Tsunenobu ^a   Fukuda, Hiroyuki ^a   Kondo, Fukuo ^a   Saisho, Hiromitsu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Arterial infusion chemotheraphy; Hepatocellular carcinoma; P glycoprotein; p53 protein

Indexed keywords

CARBOPLATIN; EPIRUBICIN; GLYCOPROTEIN P; MITOXANTRONE; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL CARCINOMA; MALE; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 33645072203     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i6.868     Document Type: Article

References (22)

1. Leveille-Webster CR, Arias IM. The biology of P-glycoprotein. J Membr Biol 1995; 143: 89-102
2. Kataoka S, Naito M, Tomida A, Tsuruo T. Resistance to anti-tumor agent-induced apoptosis in a mutant of human myeloid leukemia U937 cells. Exp Cell Res 1994; 215: 199-205
3. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318-1327
4. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967
5. Itsubo M, Ishikawa T, Toda G, Tanaka M. Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer 1994; 73: 298-303
6. Chou YY, Cheng AL, Hsu HC. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. J Gastroenterol Hepatol 1997; 12: 569-575
7. Yoshikawa M, Ebara M, Nakano T, Minoyama A, Sugiura N, Ohto M. Percutaneous transaxillary catheter insertion for hepatic artery infusion chemotherapy. AJR Am J Roentgenol 1992; 158: 885-886
8. Yoshikawa M, Ebara M, Saisho H, Hatano R, Morimoto N, Sanada M, Fukuda H, Sugiura N, Ohto M. Long-term outcome of percutaneously implanted port and catheter for hepatic arterial chemoinfusion. J Int Radiol 1997; 12: 137-142
9. Ng IO, Liu CL, Fan ST, Ng M. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am J Clin Pathol 2000; 113: 355-363
10. Nakano A, Watanabe N, Nishizaki Y, Takashimizu S, Matsuzaki S. Immunohistochemical studies on the expression of P-glycoprotein and p53 in relation to histological differentiation and cell proliferation in hepatocellular carcinoma. Hepatol Res 2003; 25: 158-165
11. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-124
12. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459-462
13. Goldsmith ME, Gudas JM, Schneider E, Cowan KH. Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem 1995; 270: 1894-1898
14. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995; 333: 1380-1385
15. Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991; 325: 1608-1614
16. Cole SP, Chanda ER, Dicke FP, Gerlach JH, Mirski SE. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 1991; 51: 3345-3352
17. Minemura M, Tanimura H, Tabor E. Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int J Oncol 1999; 15: 559-563
18. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, Washimi O, Sugiura T, Ariyoshi Y, Takahashi T, Ueda R, Takahashi T. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 1996; 14: 497-502
19. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99: 403-413
20. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998; 188: 2033-2045
21. Seth P, Katayose D, Li Z, Kim M, Wersto R, Craig C, Shanmugam N, Ohri E, Mudahar B, Rakkar AN, Kodali P, Cowan K. A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: a gene therapy approach for drug-resistant cancers. Cancer Gene Ther 1997; 4: 383-390
22. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M, Dmitrovsky E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995; 55: 5038-5042